research 62202 Network meta-analysis (NMA) of FDA-approved JAK inhibitors for alopecia areata (AA) with at least 50% hair loss per SALT score
Some JAK inhibitors are effective for significant hair regrowth in alopecia areata.
Search
for
Sort by
Research
30-60 / 1000+ results
research Multidimensional assessment of adverse events of finasteride：a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
Finasteride can cause long-term side effects like sexual dysfunction and depression.
research Cyclosporine-induced alopecia:a case report, FDA adverse event reporting system analysis and literature assessment
Cyclosporine may cause hair loss, so patients need monitoring.
research Multidimensional assessment of adverse events of finasteride:a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024
Finasteride has various adverse effects, including sexual dysfunction and mental health issues, which vary by age and gender.
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research 484 FDA cleared devices produce inconsistent platelet-rich plasma product
FDA-cleared devices often fail to produce high-quality platelet-rich plasma consistently.
research FDA-Approved (Bremelanotide, Flibanserin) and Off-Label Medications (Testosterone, Sildenafil) to Enhance Sexual Desire/Function in Women
Some medications can help increase sexual desire and function in women.
research Novel acne cream seeks FDA approval
A new acne cream effectively reduced acne in trials and awaits FDA approval.
research FDA approves label addition for PDE-5 inhibitor
The FDA approved using Cialis with Proscar for better treatment options.
research FDA vetoes labelling proposals for finasteride, dutasteride
research Retrospective Pharmacotherapeutic Evaluation of Dutasteride not Approved by US FDA for Androgenetic Alopecia in Korea
Dutasteride is highly effective for hair loss treatment in Korea, with more side effects than finasteride.
research Host-Directed FDA-Approved Drugs with Antiviral Activity against SARS-CoV-2 Identified by Hierarchical In Silico/In Vitro Screening Methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research Non-FDA-Approved Uses of Apremilast in Dermatology: A Review of Current Available literature
Apremilast shows promise for several skin conditions but needs more research.
research Unequal Protection Under the Law: Why FDA Should Use Negotiated Rulemaking to Reform the Regulation of Generic Drugs
The FDA should use negotiated rulemaking to improve generic drug safety regulations.
research Repurposing FDA approved drugs for psoriasis indications through integrated molecular docking, one-SVM algorithm, and molecular dynamics simulation approaches
Pioglitazone, Trimipramine, and Dimetindene may be repurposed to treat psoriasis.
research Host-directed FDA-approved drugs with antiviral activity against SARS-CoV-2 identified by hierarchical in silico/in vitro screening methods
Five FDA-approved drugs may help block COVID-19 virus entry.
research Not Its Crowning Glory: Obstacles for FDA in Regulating Ingested Dietary Supplements Purporting to Prevent Hair Loss
The FDA struggles to regulate hair loss supplements due to a law allowing unproven claims.
research The Possible Role of Prescribing Medications, Including Central Nervous System Drugs, in Contributing to Male-Factor Infertility (MFI): Assessment of the Food and Drug Administration (FDA) Pharmacovigilance Database
Some medications might contribute to male infertility, with finasteride showing a high number of reports.
research Repurposing of Linagliptin Similar FDA Approved Drugs as Antidiabetic Agents
Pranlukast and mirabegron may work as new diabetes drugs.
research The US FDA has approved the marketing of generic finasteride 5mg tablets by Actavis.
research Cutaneous adverse reactions associated with enfortumab vedotin: a pharmacovigilance study based on the FDA adverse event reporting system
A pharmacovigilance study using the FDA Adverse Event Reporting System identified 1,389 cases of cutaneous adverse events (AEs) associated with enfortumab vedotin (EV), a treatment for urothelial carcinoma. Common AEs included rash, pruritus, and alopecia, with severe reactions like Stevens–Johnson syndrome. The study found 44 positive safety signals, 10 of which were previously unlabeled. Most AEs occurred within the first 2 weeks of treatment, primarily in elderly males. Concomitant prednisolone use increased AE reporting and mortality, while amlodipine use decreased AE reporting. These findings underscore the need for early dermatologic surveillance and personalized safety management during EV therapy.
research Safety concerns of paternal drug exposure on fertility, pregnancy and offspring: An analysis based on the FDA adverse event reporting system
Paternal drug exposure can harm fertility, pregnancy outcomes, and offspring health, with specific drugs linked to various reproductive issues.
research 112 Post-Finasteride Syndrome – Outcomes of FDA Database
research Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system
These migraine prevention drugs can cause side effects like constipation, hair loss, injection site reactions, fatigue, and sometimes unexpected issues like Raynaud's phenomenon and weight gain.
research Game Changers: Blockbuster Small-Molecule Drugs Approved by the FDA in 2024
In 2024, the FDA approved 27 innovative small-molecule drugs, with many offering significant treatment improvements.
research Inconsistent platelet-rich plasma product from devices cleared by the US FDA: A retrospective review of clinic data
PRP treatments for hair loss need standard protocols to be reliable.
research Simultaneous spectrophotometric determination of finasteride and tadalafil in recently FDA approved Entadfi™ capsules
The methods accurately measure finasteride and tadalafil in Entadfi™ capsules for quality control.
research A disproportionality analysis of adverse events caused by pexidartinib from the FDA adverse event reporting system
Pexidartinib often causes liver issues and fatigue, especially in women.
research Innovations in skin microphysiological systems for nonclinical testing and FDA modernization
New technologies replicate human skin for testing without animals.
research PD29-07 DRUGS ASSOCIATED THE MOST WITH MALE-FACTOR INFERTILITY: ASSESSMENT OF THE 2010-2020 FOOD AND DRUG ADMINISTRATION (FDA) PHARMACOVIGILANCE DATABASE
Finasteride and testosterone are the drugs most linked to male infertility, but many other potential drugs may be under-reported.